SCHEMBL23317081

SCHEMBL23317081

CN(C)/C=C1\COC2(CCCN(C(=O)OC(C)(C)C)C2)C1=O

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 3/20 0.35
▸ AVPR1A P37288 3/20 0.34
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SCD5 Q86SK9 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ DDB1 Q16531 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ MKNK1 Q9BUB5 1/20 0.32
▸ ACACB O00763 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31282986 0.86 USP2 (0.40) USP30AVPR1AUSP2SMN1; SMN2DDB1
SCHEMBL23304781 0.84 — —
SCHEMBL23304716 0.73 USP2 (0.42) USP30USP2SMN1; SMN2HPGDMEN1
SCHEMBL3231066 0.71 AVPR1A (0.54) AVPR1ASCD5
SCHEMBL23317206 0.69 AVPR1A (0.38) USP30AVPR1AMEN1KMT2AMKNK1
SCHEMBL3597513 0.69 NR1H2 (0.45) USP2SMN1; SMN2DDB1CRBNKDM4E
SCHEMBL13052580 0.69 NR1H2 (0.45) USP2SMN1; SMN2DDB1CRBNKDM4E
SCHEMBL3597512 0.69 NR1H2 (0.45) USP2SMN1; SMN2DDB1CRBNKDM4E
SCHEMBL21041385 0.69 ESR2 (0.40) USP2SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL24417738 0.69 ESR2 (0.40) USP2SMN1; SMN2HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565504-B2 Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-03-03 — — US disclosed
CN-114929709-B Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranoside inhibitors 比奥根MA公司 2024-08-30 — — CN disclosed
US-20230060003-A1 SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2023-02-23 — — US disclosed
US-20230060003-A1 SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2023-02-23 — — US disclosed
EP-4051682-A1 SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS Biogen MA Inc. (US) 2022-09-07 — — EP disclosed
CN-114929709-A Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors 比奥根MA公司 2022-08-19 — — CN disclosed
WO-2021086966-A1 SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. (US) 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060003-A1 SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS MAN2A1, MAN2B2, ST6GAL1 USP30 4794/4885AVPR1A 957/4885USP2 3815/4885
US-12565504-B2 Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors MGAT3, ST6GAL1, MGAT1 USP30 4685/4885AVPR1A 2526/4885USP2 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback